Essentiale versus placebo added to standard of care for hepatic steatosis in NAFLD

Phase 4, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Essentiale + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change in hepatic steatosis from baseline to 6 months. Started Mar 2022; status: completed.